Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2004

View Archived Issues

Safety labeling changes for mifepristone

Pivotal study of MyVax Personalized Immunotherapy recommended to continue

Zambon withdraws from monoingredient asthma project

Positive phase II data with HspE7 in high grade cervical dysplasia

Lilly advances Isis collaborative compound into phase I

Positive findings in pilot pharmacokinetic study of Intraject sumatriptan

Preliminary results of ReceptoPharm's MS drug in microarray studies

PHER-O2 completes animal toxicity and efficacy trials at U. of Alberta

Bristol-Myers Squibb highlights pipeline progress

VivaGel well tolerated in phase I study

Approvable letter for Yaz

Anxiolytic and antidepressant effects of a novel CRF1 receptor antagonist from Ono

New combinations comprising roflumilast

Scientists at Arachnova patent topical buspirone formulations for skin conditions

Novel series of VEGFR/KDR inhibitors covered by Amgen patent

NH3 exchange inhibitors and their use described by Aventis

Researchers at Bayer describe new CCR3 antagonists

New compounds with RFRP antagonist properties

Antitumor effects and safety profile of LEP-ETU in advanced cancer

Good toxicity profile of single and multiple doses of TC-2403-12 in healthy volunteers

Effective pain control achieved with Ionsys in women after gynecological surgery

Darifenacin shows efficacy in the treatment of women with overactive bladder

Efaproxiral improves survival after WBRT in patients with brain metastasis

First clinical data reported for IGN-311 in solid tumors overexpressing Lewis Y antigen

New clinical data on the antiviral efficacy of entecavir in hepatitis B

First market introductions of strontium ranelate for postmenopausal osteoporosis

Third generation antifolate selected for preclinical development for the treatment of malaria

NEU-2000 effective in models of stroke, amyotrophic lateral sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...